Bambusa Therapeutics targets Nasdaq IPO with BBTX ticker
As seen on the 24/7 Wall St. homepage on October 9, 2026.
Bambusa Therapeutics files for Nasdaq IPO as BBTX
Bambusa Therapeutics filed its S-1 to list on Nasdaq, with BofA Securities, Evercore ISI, UBS and Cantor Fitzgerald running the books. A four-bank syndicate of that caliber signals a sizable deal, and terms are still to come, so pricing is the next thing to watch.
Continue ReadingShow less
Bambusa Therapeutics, Inc. filed its S-1 registration statement with the SEC on October 9, 2026, taking the formal first step toward a public listing on Nasdaq.
The company assembled a four-bank underwriting syndicate consisting of BofA Securities, Evercore ISI, UBS, and Cantor Fitzgerald. That combination of bulge-bracket and elite boutique banks typically signals that the issuer is targeting a meaningful deal size and expects significant institutional demand.
Pricing terms, including the share count and proposed price range, have not yet been disclosed. Those details will appear in a subsequent amended filing, making the next S-1 amendment the key document to watch as the offering takes shape.
For investors tracking the biotech IPO calendar, the filing moves Bambusa from a private company to a registered issuer, meaning the formal roadshow and pricing process can follow once the SEC completes its review cycle.